Nigel Stapleton, Vice President of Business Development and Head of Europe at Mabion, recalls that 2024 was a pivotal year for the biologics drug sector and was marked by significant advancements and challenges.
Some of those obstacles related to the increasing interest in hard-to-manufacture complex biologics such as bispecifics, ADCs and CGTs, which increase development cost, timelines and regulatory complexity.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.